Home
INSM
INSM News

Latest Insmed Incorporated (INSM) News on October 9, 2025

How Analysts Are Rethinking Insmed After Brinsupri’s Approval and New Revenue Projections

Simply Wall St.

5 days ago

How Analysts Are Rethinking Insmed After Brinsupri’s Approval and New Revenue Projections

Ohio Retirement Fund Invests in Insmed Incorporated (INSM)

Insider Monkey

7 days ago

Ohio Retirement Fund Invests in Insmed Incorporated (INSM)

Is IPF the Next Big Market Opportunity for United Therapeutics?

Zacks

8 days ago

Is IPF the Next Big Market Opportunity for United Therapeutics?

Insmed Incorporated (INSM) Rallies After FDA Approves Brinsupri, Shares Jump 9%

Insider Monkey

9 days ago

Insmed Incorporated (INSM) Rallies After FDA Approves Brinsupri, Shares Jump 9%

Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025

PR Newswire

17 days ago

Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025

Argus Research

23 days ago

Daily – Vickers Top Buyers & Sellers for 09/16/2025

MT Newswires

24 days ago

Insmed Insider Sold Shares Worth $1,453,900, According to a Recent SEC Filing

MT Newswires

24 days ago

Insmed Insider Sold Shares Worth $11,129,927, According to a Recent SEC Filing

Insmed (INSM) Reported Impressive Results from the Phase 2 Trial of Its Inhalation Powder

Insider Monkey

a month ago

Insmed (INSM) Reported Impressive Results from the Phase 2 Trial of Its Inhalation Powder

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire

a month ago

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

MT Newswires

a month ago

Insmed Insider Sold Shares Worth $26,941,272, According to a Recent SEC Filing

Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri

Pharmaceutical Technology

a month ago

Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri

UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals

Zacks

a month ago

UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals

Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It

Investor's Business Daily

a month ago

Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It

Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It

Investor's Business Daily

a month ago

Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It

Bloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution

PR Newswire

a month ago

Bloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution

Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight

GlobeNewswire

a month ago

Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 08/22/2025

How FDA Approval of BRINSUPRI for NCFB at Insmed (INSM) Has Changed Its Investment Story

Simply Wall St.

2 months ago

How FDA Approval of BRINSUPRI for NCFB at Insmed (INSM) Has Changed Its Investment Story

Magazine: Big biopharma take on the ADC challenge

Pharmaceutical Technology

2 months ago

Magazine: Big biopharma take on the ADC challenge

MT Newswires

2 months ago

Insmed Insider Sold Shares Worth $1,295,000, According to a Recent SEC Filing

Insmed To Present at September Investor Conferences

PR Newswire

2 months ago

Insmed To Present at September Investor Conferences

MT Newswires

2 months ago

Morgan Stanley Raises Price Target on Insmed to $144 From $126, Keeps Equalweight Rating

MT Newswires

2 months ago

Insmed Insider Sold Shares Worth $881,470, According to a Recent SEC Filing

MT Newswires

2 months ago

William Blair Initiates Insmed at Outperform

This ‘Strong Buy’ Pharma Stock Is Surging to New Highs

Barchart

2 months ago

This ‘Strong Buy’ Pharma Stock Is Surging to New Highs

Insmed (INSM) Gains As FDA Approves BRINSUPRI For New Market

Simply Wall St.

2 months ago

Insmed (INSM) Gains As FDA Approves BRINSUPRI For New Market

MT Newswires

3 months ago

Insmed Insider Sold Shares Worth $5,879,089, According to a Recent SEC Filing

Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110

Insider Monkey

4 months ago

Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110

Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107

Insider Monkey

4 months ago

Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107

Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating

Insider Monkey

4 months ago

Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating

Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results

Insider Monkey

4 months ago

Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans

BioPharma Dive

4 months ago

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans

Insmed (INSM) Soars After Raising $650 million

Insider Monkey

4 months ago

Insmed (INSM) Soars After Raising $650 million

Insmed Inc (INSM) Soars 30% on Impressive Study

Insider Monkey

4 months ago

Insmed Inc (INSM) Soars 30% on Impressive Study

MT Newswires

4 months ago

Insmed Insider Sold Shares Worth $5,148,024, According to a Recent SEC Filing

MT Newswires

4 months ago

Insmed Prices $750 Million Common Stock Offering

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

PR Newswire

4 months ago

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)

Insider Monkey

4 months ago

Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)

MT Newswires

4 months ago

Insmed Plans $650 Million Public Offering

Insmed Announces Proposed $650 Million Public Offering of Common Stock

PR Newswire

4 months ago

Insmed Announces Proposed $650 Million Public Offering of Common Stock

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

Benzinga

4 months ago

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

MT Newswires

4 months ago

Update: BofA Securities Raises Insmed Price Target to $109 From $94, Maintains Buy Rating

Insmed Stock Jumps 29% on Encouraging PAH Study Results

Zacks

4 months ago

Insmed Stock Jumps 29% on Encouraging PAH Study Results

Insmed Stock Skyrockets Following Experimental Drug Trial Results

Barrons.com

4 months ago

Insmed Stock Skyrockets Following Experimental Drug Trial Results

Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia

Investor's Business Daily

4 months ago

Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia

MT Newswires

4 months ago

Sector Update: Health Care

MT Newswires

4 months ago

Top Premarket Gainers

MT Newswires

4 months ago

Insmed Says Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

PR Newswire

4 months ago

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

MT Newswires

4 months ago

Insmed Insider Sold Shares Worth $878,292, According to a Recent SEC Filing

MT Newswires

4 months ago

Insmed Insider Sold Shares Worth $451,535, According to a Recent SEC Filing

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire

4 months ago

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

MT Newswires

4 months ago

Insmed Insider Sold Shares Worth $1,833,779, According to a Recent SEC Filing

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

PR Newswire

4 months ago

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

MT Newswires

5 months ago

Insmed Insider Sold Shares Worth $1,886,957, According to a Recent SEC Filing

MT Newswires

5 months ago

Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

PR Newswire

5 months ago

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

MT Newswires

5 months ago

Insmed Insider Sold Shares Worth $633,654, According to a Recent SEC Filing

MT Newswires

5 months ago

Insmed Insider Sold Shares Worth $708,681, According to a Recent SEC Filing

Insmed Incorporated (INSM): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

Insider Monkey

5 months ago

Insmed Incorporated (INSM): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects

Zacks

5 months ago

Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects

MT Newswires

5 months ago

Jefferies Initiates Coverage on Insmed With Buy Rating, $105 Price Target

Analysts Are Updating Their Insmed Incorporated (NASDAQ:INSM) Estimates After Its First-Quarter Results

Simply Wall St.

5 months ago

Analysts Are Updating Their Insmed Incorporated (NASDAQ:INSM) Estimates After Its First-Quarter Results

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates

Zacks

5 months ago

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates

MT Newswires

5 months ago

UBS Adjusts Price Target on Insmed to $109 From $110, Maintains Buy Rating

Is Insmed Incorporated (INSM) the Best Cancer Stock to Invest in for Long-Term Gain?

Insider Monkey

5 months ago

Is Insmed Incorporated (INSM) the Best Cancer Stock to Invest in for Long-Term Gain?

MT Newswires

5 months ago

RBC Trims Price Target on Insmed to $99 From $100, Keeps Outperform Rating

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

Zacks

5 months ago

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

MT Newswires

5 months ago

Insmed Q1 Net Loss Widens, Revenue Increases; 2025 Revenue Guidance Maintained

Associated Press Finance

5 months ago

Insmed: Q1 Earnings Snapshot

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

PR Newswire

5 months ago

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

Insmed Incorporated (INSM): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy

Insider Monkey

5 months ago

Insmed Incorporated (INSM): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy

MT Newswires

5 months ago

Insmed Insider Sold Shares Worth $495,668, According to a Recent SEC Filing

Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline

Zacks

5 months ago

Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline

Insmed Incorporated (INSM): Among Billionaire George Soros’ Mid-Cap Stocks With Huge Upside Potential

Insider Monkey

5 months ago

Insmed Incorporated (INSM): Among Billionaire George Soros’ Mid-Cap Stocks With Huge Upside Potential

Insmed To Present at the BofA Securities 2025 Health Care Conference

PR Newswire

5 months ago

Insmed To Present at the BofA Securities 2025 Health Care Conference

MT Newswires

5 months ago

Insmed to Redeem $569.5 Million of Convertible Senior Notes

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

PR Newswire

6 months ago

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

Insmed Incorporated (INSM): Among Takeover Rumors Hedge Funds Are Buying

Insider Monkey

6 months ago

Insmed Incorporated (INSM): Among Takeover Rumors Hedge Funds Are Buying

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

PR Newswire

6 months ago

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

PR Newswire

6 months ago

Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

MT Newswires

6 months ago

Insmed Insider Sold Shares Worth $479,177, According to a Recent SEC Filing

Is Insmed Incorporated (INSM) the Best Long Term Growth Stock to Buy According to Billionaires?

Insider Monkey

6 months ago

Is Insmed Incorporated (INSM) the Best Long Term Growth Stock to Buy According to Billionaires?

Insmed Incorporated (INSM): Insiders Were Dumping in Q1 2025

Insider Monkey

6 months ago

Insmed Incorporated (INSM): Insiders Were Dumping in Q1 2025

Is Insmed Incorporated (INSM) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey

6 months ago

Is Insmed Incorporated (INSM) a Promising Biotech Stock According to Wall Street Analysts

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

PR Newswire

6 months ago

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

Insmed Incorporated (INSM): Among the Best Biotech Stocks to Buy According to Billionaires

Insider Monkey

7 months ago

Insmed Incorporated (INSM): Among the Best Biotech Stocks to Buy According to Billionaires

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire

7 months ago

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

MT Newswires

7 months ago

UBS Adjusts Price Target on Insmed to $110 From $105, Maintains Buy Rating

MT Newswires

7 months ago

Insmed Insider Sold Shares Worth $1,989,797, According to a Recent SEC Filing

MT Newswires

7 months ago

Insmed to Benefit From Strong Launch of Brensocatib for Lung Disease, RBC Says

MT Newswires

7 months ago

RBC Capital Initiates Insmed at Outperform With $100 Price Target

International Markets and Insmed (INSM): A Deep Dive for Investors

Zacks

7 months ago

International Markets and Insmed (INSM): A Deep Dive for Investors

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

PR Newswire

8 months ago

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

MT Newswires

8 months ago

UBS Adjusts Insmed Price Target to $105 From $84, Maintains Buy Rating

MT Newswires

8 months ago

Truist Securities Adjusts Insmed Price Target to $108 From $105, Maintains Buy Rating

Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

Zacks

8 months ago

Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

Insmed Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

8 months ago

Insmed Full Year 2024 Earnings: EPS Misses Expectations

Insmed Inc (INSM) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

GuruFocus.com

8 months ago

Insmed Inc (INSM) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Share on Social Networks: